Biologic Specimen and Data Repository Information Coordinating Center
Home > Studies > TCD

Resources Available

Study Datasets Only

Study Documents

PDF Data Dictionary (PDF - 840.6 KB)
PDF Forms (PDF - 8.0 MB)

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message.

If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

T-Cell Depletion in Unrelated Donor Marrow Transplantation (TCD)

Clinical Trials URL:
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on November 10, 2005
Study Dates: 1993-2005
Consent: Unrestricted Consent
Commercial Use Restrictions: No
NHLBI Division: DBDR
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information


To evaluate the impact of ex vivo T-Cell Depletion of marrow as compared with unmodified grafts on disease-free survival in recipients of unrelated donor bone marrow transplants.


Chronic graft-versus-host disease (cGVHD) is a major complication and a leading cause of post hematopoietic stem cell transplantion morbidity and mortality. Animal studies suggest that cGVHD is mediated by mature donor T cells that react against disparate recipient histocompatibility antigens. T cell-depletion of donor marrow before infusion into the recipient may ameliorate or prevent GvHD. Unfortunately, since donor T cells also play a key role in mediating graft-versus-tumor (GVT) effects, aggresive GVHD prevention strategies in patients with malignant disease may compromise beneficial antineoplastic GVT effects.


410 patients with hemotologic malignancies were randomized at 15 participating transplantation centers, 203 patients were randomized to receive t-cell-depleted marrow and cyclosporine (TCD arm) and 207 to receive methotrexate and cyclosporine after transplantation of t-cell-replete marrow.


In spite of a significant reduction of acute GHVD, TCD did not reduce the incidence of cGVHD or improve survival in patients who developed cGVHD. (Blood. 2005; 106(9):3308-3313)